Myalgia

Herbal medicinal product: Eucalypti aetheroleumArray,Array,Array, F: Assessment finalised

Retrieved on: 
Thursday, April 18, 2024
Eucalyptus oil, Bronchitis, Spasm, Seizure, System, Risk, Inflammation, Patient, Lung, Monograph, Committee, Inhalation, Steam, Herbal medicine, Date, Asthma, Heart failure, Plant, Mouth, Infection, Skin, Fever, Myalgia, Water, Larynx, Medicine, Dietary supplement

Herbal medicinal product: Eucalypti aetheroleumArray,Array,Array, F: Assessment finalised

Key Points: 


Herbal medicinal product: Eucalypti aetheroleumArray,Array,Array, F: Assessment finalised

Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Retrieved on: 
Tuesday, March 26, 2024
COVID-19 vaccine, Risk, Headache, COVID-19, Ageing, Public, Vaccine, MRNA, Messenger, Chills, SARS-CoV-2, Myalgia, Clinical trial, Safety, Omicron, Fatigue

"We are excited to announce our fourth infectious disease vaccine program with positive Phase 3 data, further validating our robust mRNA platform," said Stephane Bancel, Chief Executive Officer of Moderna.

Key Points: 
  • "We are excited to announce our fourth infectious disease vaccine program with positive Phase 3 data, further validating our robust mRNA platform," said Stephane Bancel, Chief Executive Officer of Moderna.
  • "mRNA-1283 is a critical component of our combination vaccine against flu and COVID-19, mRNA-1083, and this milestone gives us confidence in our ability to bring this much needed vaccine to market."
  • In the NextCOVE (NCT05815498) Phase 3 pivotal trial, mRNA-1283 was shown to elicit a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2, compared to mRNA-1273.222.
  • A detailed analysis of the Phase 3 clinical trial data for mRNA-1283 will be shared at the Company's Vaccines Day event on March 27 and presented at upcoming scientific conferences.

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Retrieved on: 
Tuesday, March 26, 2024
Connected, HIV-1, Amazon Prime Video, Breast milk, Face, Hypoesthesia, Patient, Chronic pain, Clostridioides, Heartburn, Lymph, Magnesium, Diarrhea, Myalgia, Spine, Allergy, Muscle weakness, Vonoprazan, Stomach, Vitamin, Dizziness, Potassium, Hip, Risk, Tongue, Chills, DTC, Safety, Food, PPI, Rash, Food and Drug Administration, GERD, Enzyme inhibitor, Skin, Esophagitis, HIV, Rilpivirine, Kidney, FDA, Esophagus, B-12, Weakness, Infection, Indigestion, Smart TV, Seizure, Inflammation, Polyp, Calcium, Extrapyramidal system, Bone fracture, Nausea, Spasm, Urine, Fever, Clostridioides difficile, Bleeding, Blood, Wrist, Blister, Vitamin B12, Human, Medicine, Pharmaceutical industry

FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announces the launch of its new broadcast ad and full-scale, Direct-to-Consumer (DTC) campaign, “VOQUEZNA Can Kick Some Acid,” to raise awareness of its powerful first-in-class treatment and encourage people to speak to their doctor about this new treatment option. VOQUEZNA (vonoprazan) is indicated for the healing and maintenance of healing of all severities of Erosive Esophagitis (EE), also referred to as Erosive GERD, and for the relief of related heartburn. VOQUEZNA represents the first major innovation to the U.S. Erosive GERD market in over 30 years.1

Key Points: 
  • The campaign will also be featured on consumer-facing platforms across Facebook, Instagram, waiting room TVs in doctor offices, and digital banner ads.
  • “Phathom is excited to launch our first campaign directly to, and for, the people whose lives we strive to improve every day.
  • To view a video of the “VOQUEZNA Can Kick Some Acid” commercial, click here.
  • Talk with your healthcare provider about the possibility of fundic gland polyps if you have been on VOQUEZNA for a long time.

EMUAID® Unveils Breakthrough Natural Pain Relief Cream, Now Available at Walgreens Nationwide

Retrieved on: 
Tuesday, March 26, 2024
Cream, Arthralgia, Allantoin, First aid, Nonsteroidal anti-inflammatory drug, Arthritis, Arnica, Myalgia, Pain management, Pain, Steroid, Emu oil, Diabetic neuropathy, Cosmetics

This marks a significant expansion of EMUAID®'s reach in providing effective, natural alternatives for topical pain management to consumers nationwide.

Key Points: 
  • This marks a significant expansion of EMUAID®'s reach in providing effective, natural alternatives for topical pain management to consumers nationwide.
  • EMUAID® announces the launch of its innovative Pain Relief Cream in Walgreens stores across the United States.
  • The availability of EMUAID®'s Pain Relief Cream in the First Aid section at Walgreens strengthens the brand's accessibility, making it easier for consumers to experience the benefits of natural pain relief.
  • EMUAID® Pain Relief Cream is now available in the First Aid Section at Walgreens stores nationwide.

Local Heritage and Aging Innovation Come Together at New Aegis Living Community in Ballard

Retrieved on: 
Wednesday, March 20, 2024
Element, Health, Longevity, Aegis, Exercise, Compass, Inflammation, Light, Sleep, Food, Criterion, Meal, Salmon, Market Street, Nature, Wood, Dahlin, Glass, Sculpture, Architecture, Diet, Love, Water, Deadliest Catch, Myalgia, Immune system, Music, Hygge, Burke–Gilman Trail, Nightclub

BELLEVUE, Wash., March 20, 2024 /PRNewswire/ -- Aegis Living, a leader in senior living and memory care, has opened its 37th community in Seattle's Ballard neighborhood, Aegis Living Ballard. Located centrally on Market Street, the new community blends a distinctly Northwest aesthetic with Scandinavian heritage and is a testament to Ballard's rich maritime history and unique neighborhood.

Key Points: 
  • BELLEVUE, Wash., March 20, 2024 /PRNewswire/ -- Aegis Living , a leader in senior living and memory care, has opened its 37th community in Seattle's Ballard neighborhood, Aegis Living Ballard .
  • "Ballard is an eclectic urban neighborhood known for its vibrancy and vitality, which made for the perfect location for our newest community, Aegis Living Ballard," said Aegis Living founder and CEO Dwayne Clark.
  • In addition to its warm, welcoming design, Aegis Living Ballard prioritizes wellness and longevity at the forefront of its care.
  • Aegis Living Ballard is located at 949 NW Market Street, Seattle, WA 98107.

RAKxa INTEGRATIVE WELLNESS MAKES ITS U.S. DEBUT AT THE ST. REGIS ASPEN RESORT, BRINGING AWARD-WINNING THAI WELLNESS EXPERTISE TO COLORADO'S PREMIER MOUNTAIN RETREAT

Retrieved on: 
Monday, March 11, 2024
Health, Ayurveda, Relaxation, Circadian rhythm, Skiing, Inflammation, Call-progress tone, Resort, Traditional Thai medicine, Acupressure, Massage, Myalgia, ASPEN, Tourism

BANGKOK and ASPEN, Colo., March 11, 2024 /PRNewswire/ -- RAKxa Integrative Wellness, an award-winning wellness retreat in Thailand, announced its debut in The U.S., with RAKxa Wellness Spa at The St. Regis Aspen Resort in the iconic destination, Aspen, Colorado. Opening its doors this winter, this all-around health-focused spa combines the wisdom and innovative techniques from RAKxa's Thailand roots with a sophisticated and relaxing spa experience and complementary treatments to help rebalance the body and mind.

Key Points: 
  • BANGKOK and ASPEN, Colo., March 11, 2024 /PRNewswire/ -- RAKxa Integrative Wellness, an award-winning wellness retreat in Thailand, announced its debut in The U.S., with RAKxa Wellness Spa at The St. Regis Aspen Resort in the iconic destination, Aspen, Colorado.
  • A true highlight featured on RAKxa's first state-side spa menu is the Ballancer®Pro – a revolutionary Lymphatic Drainage Suit at the forefront of modern-day wellness technology.
  • Additional highlights include the introduction of two new signature treatments to the menu, designed to enhance the guest experience at RAKxa Wellness Spa.
  • "Aspen is not just a destination; it's an experience, and RAKxa Wellness Spa at The St. Regis Aspen Resort is poised to elevate that experience to new heights," said Heather Steenge-Hart, Area General Manager for Luxury Mountain Resorts and The St. Regis Aspen Resort.

ACTG CROI Presentation Demonstrates Superiority of HepB-CpG Vaccine Over Conventional Hepatitis B Vaccine Among People Living With HIV Who Have Not Previously Responded to Vaccination

Retrieved on: 
Wednesday, March 6, 2024
Infection, Bangladesh Technical Education Board, CD4, Superior, Hepatitis B, Headache, CpG, Fungal infection, NIAID, CROI, ACTG, University of Cincinnati, Weill Cornell Medicine, Conference, Vaccination, University, ART, Fatigue, Virus, Myalgia, White, Black, Protocol, UM1, Massachusetts General Hospital, Male, Hepatitis, HIV, University of North Carolina, Vaccine

These data demonstrated that the HepB-CpG vaccine achieved up to 99 percent protection among people living with HIV who had previously not responded to conventional hepatitis B vaccines, a noteworthy increase compared to the protection achieved by conventional vaccines.

Key Points: 
  • These data demonstrated that the HepB-CpG vaccine achieved up to 99 percent protection among people living with HIV who had previously not responded to conventional hepatitis B vaccines, a noteworthy increase compared to the protection achieved by conventional vaccines.
  • People living with HIV, especially those with lower CD4 counts, often do not develop protective antibodies after receiving conventional hepatitis B vaccines.
  • The HepB-CpG (HEPLISAV-B®) vaccine includes a TLR-9 agonist adjuvant (CpG 1018® adjuvant) and is known to achieve high protection against hepatitis B among people living with HIV, but until now there have been limited data about its protection among people living with HIV who have not responded to conventional hepatitis B vaccines.
  • “Hepatitis B remains a significant issue for people living with HIV, as having both viruses increases the likelihood of liver complications,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

Retrieved on: 
Friday, February 23, 2024
Fever, European Commission, EMA, ALS, Committee, MND, Myalgia, Intracranial pressure, BIIB, Cerebrospinal fluid, Pain, Hope, Biogen, European, SOD1, Arthralgia, Civil service commission, Biomarker, Fatigue, CHMP, AFL, European Medicines Agency, Protein, Disease, UZ Leuven, Mutation, Myelitis, Neurology, Aseptic meningitis, Research, Chronic pain, Vaccine

If authorized by the European Commission (EC), QALSODY will be the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).

Key Points: 
  • If authorized by the European Commission (EC), QALSODY will be the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).
  • “The CHMP’s positive opinion reinforces the impact QALSODY can have in SOD1-ALS and further demonstrates Biogen’s commitment to address the unmet needs of people living with ALS and neuromuscular diseases,” said Priya Singhal, M.D., M.P.H., Head of Development at Biogen.
  • Trends towards improvement in the physical abilities of participants who received QALSODY were seen compared to those who received placebo, as measured by the ALS Functional Ratings Scale-Revised (ALSFRS-R).
  • Serious neurologic events, including myelitis and/or radiculitis; papilledema and elevated intracranial pressure; and aseptic meningitis have also been reported.

FSIS Public Health Alert - Listeria monocytogenes

Retrieved on: 
Friday, February 9, 2024
USDA, Office for Civil Rights, RTE, Diarrhea, Food safety, Pregnancy, FDA, Food, Cheese, Meat, Human, Gastrointestinal tract, Fever, Stillbirth, CHICKEN, Headache, Quality assurance, Poultry, Civil and political rights, Myalgia, Eating, Listeriosis, Independence Avenue, Person, BLACK, Infection, Listeria monocytogenes, Food and Drug Administration, Confusion, BEST, FSIS, TDD, Dietary supplement

FSIS is issuing this public health alert to ensure that consumers are aware that these products, which bear the USDA mark of inspection, should not be consumed.

Key Points: 
  • FSIS is issuing this public health alert to ensure that consumers are aware that these products, which bear the USDA mark of inspection, should not be consumed.
  • As more information becomes available, FSIS will update this public health alert.
  • The following products subject to the public health alert are [ view labels ]:
    10.53-oz.
  • The problem was discovered when the firm notified FSIS that they used FDA-regulated cotija cheese that may be contaminated with Listeria monocytogenes to produce burrito products.

Superior HealthPlan Recognized as a Best Place for Working Parents® in Texas

Retrieved on: 
Tuesday, February 6, 2024
CNC, Parent, Centene Corporation, Child, Diabetes, Myalgia, Health, Parental leave, Organization, Residential care

AUSTIN, Texas, Feb. 6, 2024 /PRNewswire/ -- Superior HealthPlan ("Superior"), a leading managed care organization in Texas and wholly owned subsidiary of Centene Corporation (NYSE: CNC), today announced it has been named a Best Place for Working Parents® for a fourth consecutive year. This designation is supported by Early Matters Greater Austin, a joint initiative from United Way for Greater Austin and E3 Alliance.

Key Points: 
  • AUSTIN, Texas, Feb. 6, 2024 /PRNewswire/ -- Superior HealthPlan ("Superior"), a leading managed care organization in Texas and wholly owned subsidiary of Centene Corporation (NYSE: CNC), today announced it has been named a Best Place for Working Parents® for a fourth consecutive year.
  • "Supporting working parents with family-friendly policies, benefits, and resources continues to be a priority for our organization," said Superior HealthPlan president and CEO, Mark Sanders.
  • Superior was recognized in 2019 as a Family-Friendly Workplace , one of the first 30 organizations in Austin to receive the honor.
  • Ever since, Superior has been named a Best Place for Working Parents®, adding multiple benefits aimed at further supporting employees:
    Parental & Caregiver Leave.